South Africa


  • Industry: Pharmaceutical
  • Type: Business and industry issue
  • Date: 2011/05/10


KPMG’s Pharmaceuticals team offers industry advisory, assisting businesses from biotechnology start-ups to large multinational pharmaceutical companies.

The Tablet April 2011 

The Tablet of April 2011 cuts through the controversy surrounding the value of comparative effectiveness research in the United States, the world’s biggest healthcare spender.
Download Now
PDF files require Adobe Reader to view

The US Institute of Medicine reports that more than half the drug treatments provided to patients lack clear evidence of any effectiveness. This has made comparative effectiveness research (CER) the focus of attention and controversy following the 2009 healthcare reform bill.


CER compares the effectiveness of different treatments. This paper looks at the implications of CER for spending on pharmaceutical R&D, profit margins, market focus and other factors including the greater involvement of payers, and opportunities with CER.